

Special Issue

Resistance to Targeted Therapies in Human Cancer

Message from the Guest Editors

Targeted therapies that inhibit the action of cancer-specific molecules have been widely used as standard of care treatments for multiple solid tumors. Despite the benefits of targeted therapies with remarkably improved survival outcomes and reduced side effects, the high prevalence of innate and acquired resistances to the therapies, leading to tumor recurrence and metastasis after treatment, remains a major problem in the treatment of cancers, requiring a need to discover novel biomarkers and combination treatment strategies to overcome the resistance to conventional targeted therapies in human cancers.

This Special Issue will cover all aspects of cancer targeted therapies, including mechanisms underlying the innate and acquired resistances to anti-cancer drugs targeting specific molecules, screening and identification of potential actionable therapeutic targets and their associated drugs, and new therapeutic strategies for refractory cancers with drug resistance.

Guest Editors

Prof. Dr. Jeong-yeon Lee

Department of Pathology, College of Medicine, Hanyang University, Seoul, Republic of Korea

Prof. Dr. Kyung-min Lee

Department of Life Science, Hanyang University, Seoul, Republic of Korea

Deadline for manuscript submissions

closed (30 November 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/85670

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).